Advertisement

Supportive Care in Cancer

, Volume 27, Issue 3, pp 783–791 | Cite as

Radiation-induced nausea and vomiting: a comparison between MASCC/ESMO, ASCO, and NCCN antiemetic guidelines

  • Erin McKenzie
  • Pearl Zaki
  • Srinivas Raman
  • Robert Olson
  • Thomas McFarlane
  • Carlo DeAngelis
  • Stephanie Chan
  • William Pidduck
  • Yasmeen Razvi
  • Ahmad Bushehri
  • Edward ChowEmail author
Review Article

Abstract

Purpose

Radiation-induced nausea and vomiting (RINV) can affect 50–80% of patients undergoing radiotherapy and negatively impacts quality of life. This review aimed to compare the most recent RINV antiemetic guidelines produced by the Multinational Association for Supportive Care in Cancer (MASCC), the European Society of Clinical Oncology (ESMO), the American Society of Clinical Oncology (ASCO), and the National Comprehensive Cancer Network (NCCN). Future improvements to the guidelines and the need for further research in RINV were also discussed.

Methods

Antiemetic guidelines produced by MASCC/ESMO, ASCO, and NCCN were examined to identify similarities, differences, and inadequacies within the guidelines.

Results

Areas of dissension within the guidelines include the addition of dexamethasone to moderate-risk antiemetic regimens, the prophylactic treatment of RINV in the low-risk categories, and the appropriate treatment for breakthrough emesis. The guidelines are in accordance that high-risk radiotherapy regimens should be treated prophylactically with a serotonin receptor antagonist and for those undergoing concurrent chemotherapy and radiotherapy, antiemetic treatment should be prescribed according to the emetic risk associated with their respective chemotherapy regimen. Low- and minimal-risk recommendations are based on low-level evidence and informal consensus.

Conclusion

RINV is a frequent and distressing side effect of radiotherapy and requires further research to establish effective antiemetic guidelines and ensure optimal treatment outcomes.

Keywords

Nausea and vomiting Antiemetics Radiation oncology Antiemetic guidelines 

Notes

Funding information

The authors received financial support from the Bratty Family Fund, Michael and Karyn Goldstein Cancer Research Fund, Joey and Mary Furfari Cancer Research Fund, Pulenzas Cancer Research Fund, Joseph and Silvana Melara Cancer Research Fund, and Ofelia Cancer Research Fund.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Dennis K, Zhang L, Lutz S, van Baardwijk A, van der Linden Y, Holt T, Arnalot PF, Lagrange JL, Maranzano E, Liu R, Wong KH, Wong LC, Vassiliou V, Corn BW, de Angelis C, Holden L, Wong CS, Chow E (2012) International patterns of practice in the management of radiation therapy-induced nausea and vomiting. Int J Radiat Oncol Biol Phys 84(1):49–60.  https://doi.org/10.1016/j.ijrobp.2012.02.031 CrossRefGoogle Scholar
  2. 2.
    Maranzano E, De Angelis V, Pergolizzi S, Lupattelli M, Frata P, Spagnesi S et al (2009) A prospective observational trial on emesis in radiotherapy: analysis of 1020 patients recruited in 45 Italian radiation oncology centres. Radiother Oncol 94(1):36–41.  https://doi.org/10.1016/j.radonc.2009.11.001. CrossRefGoogle Scholar
  3. 3.
    Henriksson R, Lomberg H, Israelsson G, Zackrisson B, Franzén L (1992) The effect of ondansetron on radiation-induced emesis and diarrhoea. Acta Oncol 31(7):767–769CrossRefGoogle Scholar
  4. 4.
    Enblom A, Bergius Axelsson B, Steineck G, Hammar M, Börjeson S (2008) One third of patients with radiotherapy-induced nausea consider their antiemetic treatment insufficient. Support Care Cancer 17(1):23–32.  https://doi.org/10.1007/s00520-008-0445-x CrossRefGoogle Scholar
  5. 5.
    Pirri C, Bayliss E, Trotter J, Olver IN, Katris P, Drummond P, Bennett R (2013) Nausea still the poor relation in antiemetic therapy? The impact on cancer patients’ quality of life and psychological adjustment of nausea, vomiting and appetite loss, individually and concurrently as part of a symptom cluster. Support Care Cancer 21(3):735–748.  https://doi.org/10.1007/s00520-012-1574-9 CrossRefGoogle Scholar
  6. 6.
    Feyer PC, Stewart AL, Titlbach OJ (1998) Aetiology and prevention of emesis induced by radiotherapy. Support Care Cancer 6(3):253–260CrossRefGoogle Scholar
  7. 7.
    Dennis K, Nguyen J, Presutti R, DeAngelis C, Tsao M, Danjoux C, Barnes E, Sahgal A, Holden L, Jon F, Wong S, Chow E (2012) Prophylaxis of radiotherapy-induced nausea and vomiting in the palliative treatment of bone metastases. Support Care Cancer 20(8):1673–1678.  https://doi.org/10.1007/s00520-011-1258-x CrossRefGoogle Scholar
  8. 8.
    Aass N, Håtun DE, Thoresen M, Fosså SD (1997) Prophylactic use of tropisetron or metoclopramide during adjuvant abdominal radiotherapy of seminoma stage I: a randomised, open trial in 23 patients. Radiother Oncol 45(2):125–128CrossRefGoogle Scholar
  9. 9.
    Feyer P, Seegenschmiedt MH, Steingraeber M (2005) Granisetron in the control of radiotherapy-induced nausea and vomiting: a comparison with other antiemetic therapies. Support Care Cancer 13(9):671–678.  https://doi.org/10.1007/s00520-004-0766-3 CrossRefGoogle Scholar
  10. 10.
    Lanciano R, Sherman DM, Michalski J, Preston AJ, Yocom K, Friedman C (2001) The efficacy and safety of once-daily Kytril® (granisetron hydrochloride) tablets in the prophylaxis of nausea and emesis following fractionated upper abdominal radiotherapy. Cancer Investig 19(8):763–772CrossRefGoogle Scholar
  11. 11.
    Priestman TJ, Roberts JT, Lucraft H, Collis CH, Adams M, Upadhyaya BK, Priestman S (1990) Results of a randomized, double-blind comparative study of ondansetron and metoclopramide in the prevention of nausea and vomiting following high-dose upper abdominal irradiation. Clin Oncol 2(2):71–75CrossRefGoogle Scholar
  12. 12.
    Priestman TJ, Roberts JT, Upadhyaya BK (1993) A prospective randomized double-blind trial comparing ondansetron versus prochlorperazine for the prevention of nausea and vomiting in patients undergoing fractionated radiotherapy. Clin Oncol 5(6):358–363CrossRefGoogle Scholar
  13. 13.
    Danjoux CE, Rider WD, Fitzpatrick PJ (1979) The acute radiation syndrome: a memorial to William Michael Court-Brown. Clin Radiol 30(5):581–584CrossRefGoogle Scholar
  14. 14.
    Wong RKS, Paul N, Ding K, Whitehead M, Brundage M, Fyles A et al (2006) 5-Hydroxytryptamine-3 receptor antagonist with or without short-course dexamethasone in the prophylaxis of radiation induced emesis: a placebo-controlled randomized trial of the National Cancer Institute of Canada Clinical Trials Group (SC19). J Clin Oncol 24(21):3458–3464.  https://doi.org/10.1200/JCO.2005.04.4685 CrossRefGoogle Scholar
  15. 15.
    Kirkbride P, Bezjak A, Pater J, Zee B, Palmer MJ, Wong R, Cross P, Gulavita S, Blood P, Sun A, Dundas G, Ganguly PK, Lim J, Chowdhury AD, Kumar SE, Dar AR (2000) Dexamethasone for the prophylaxis of radiation-induced emesis: a National Cancer Institute of Canada Clinical Trials Group Phase III Study. J Clin Oncol 18(9):1960–1966.  https://doi.org/10.1200/JCO.2000.18.9.1960 CrossRefGoogle Scholar
  16. 16.
    Yamamoto K, Nohara K, Furuya T, Yamatodani A (2005) Ondansetron, dexamethasone and an NK1 antagonist block radiation sickness in mice. Pharmacol Biochem Behav 82(1):24–29.  https://doi.org/10.1016/j.pbb.2005.07.007 CrossRefGoogle Scholar
  17. 17.
    Dennis K, De Angelis C, Jon F, Lauzon N, Pasetka M, Holden L et al (2014) Aprepitant and granisetron for the prophylaxis of radiotherapy-induced nausea and vomiting after moderately emetogenic radiotherapy for bone metastases: a prospective pilot study. Curr Oncol 21(6):760–e767.  https://doi.org/10.3747/co.21.2051 CrossRefGoogle Scholar
  18. 18.
    Rowbottom L, Pasetka M, McDonald R, Hunyh L, Raman S, DeAngelis C, Chow E (2015) Efficacy of granisetron and aprepitant in a patient who failed ondansetron in the prophylaxis of radiation induced nausea and vomiting: a case report. Ann Palliat Med 4(1):32–34.  https://doi.org/10.3978/j.issn.2224-5820.2015.01.01. Google Scholar
  19. 19.
    Roila F, Molassiotis A, Herrstedt J, Aapro M, Gralla RJ, Bruera E, Clark-Snow RA, Dupuis LL, Einhorn LH, Feyer P, Hesketh PJ, Jordan K, Olver I, Rapoport BL, Roscoe J, Ruhlmann CH, Walsh D, Warr D, van der Wetering M, participants of the MASCC/ESMO Consensus Conference Copenhagen 2015 (2016) 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. Ann Oncol 27(5):119–133.  https://doi.org/10.1093/annonc/mdw270 CrossRefGoogle Scholar
  20. 20.
    Hesketh PJ, Kris MG, Basch E, Bohlke K, Barbour SY, Clark-Snow RA, Danso MA, Dennis K, Dupuis LL, Dusetzina SB, Eng C, Feyer PC, Jordan K, Noonan K, Sparacio D, Somerfield MR, Lyman GH (2017) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Clin Oncol 35(28):3240–3261.  https://doi.org/10.1200/JCO.2017.74.4789 CrossRefGoogle Scholar
  21. 21.
    Ettinger DS, Berger MJ, Ashton J, Barbour S, Bergsbaken J, Bierman P et al (2017) NCCN Guidelines Version 2.2017 Panel Members AntiemesisGoogle Scholar
  22. 22.
    Maranzano E, Feyer PC, Molassiotis A, Rossi R, Clark-Snow RA, Olver I et al (2005) Evidence-based recommendations for the use of antiemetics in radiotherapy. Radiother Oncol 76(3):227–233.  https://doi.org/10.1016/j.radonc.2005.07.002 CrossRefGoogle Scholar
  23. 23.
    Poonacha TK, Go RS (2011) Level of scientific evidence underlying recommendations arising from the National Comprehensive Cancer Network clinical practice guidelines. J Clin Oncol 29(2):186–191.  https://doi.org/10.1200/JCO.2010.31.6414 CrossRefGoogle Scholar
  24. 24.
    European Society for Medical Oncology (ESMO) Guidelines Committee (2018) SOPs/Instructions for authors and templates for standard ESMO Clinical Practice Guidelines (CPGs) and ESMO-MCBS scores. Retrieved from https://www.esmo.org/content/download/77789/1426712/file/ESMO-Clinical-Practice-Guidelines-Standard-Operating-Procedures.pdf
  25. 25.
    Basch E, Hesketh PJ, Kris MG, Prestrud AA, Temin S, Lyman GH (2011) Antiemetics: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 7(6):395–398.  https://doi.org/10.1200/jco.2010.34.4614. CrossRefGoogle Scholar
  26. 26.
    Roila F, Herrstedt J, Aapro M, Gralla RJ, Einhorn LH, Ballatori E, Bria E, Clark-Snow RA, Espersen BT, Feyer P, Grunberg SM, Hesketh PJ, Jordan K, Kris MG, Maranzano E, Molassiotis A, Morrow G, Olver I, Rapoport BL, Rittenberg C, Saito M, Tonato M, Warr D, On behalf of the ESMO/MASCC Guidelines Working Group (2010) Guideline update for MASCC and ESMO in the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting: results of the Perugia consensus conference. Ann Oncol 21(5):232–243.  https://doi.org/10.1093/annonc/mdq194 CrossRefGoogle Scholar
  27. 27.
    The Italian Group for Antiemetic Research in Radiotherapy (1999) Radiation-induced emesis: a prospective observational multicenter Italian trial. Int J Radiat Oncol Biol Phys 44(3):619–625Google Scholar
  28. 28.
    Spitzer TR, Friedman CJ, Bushnell W, Frankel SR, Raschko J (2000) Double-blind, randomized, parallel-group study on the efficacy and safety of oral granisetron and oral ondansetron in the prophylaxis of nausea and vomiting in patients receiving hyperfractionated total body irradiation. Bone Marrow Transplant 26(2):203–210.  https://doi.org/10.1038/sj.bmt.1702479 CrossRefGoogle Scholar
  29. 29.
    Dennis K, Makhani L, Maranzano E, Feyer P, Zeng L, De Angelis C et al (2013) Timing and duration of 5-HT3 receptor antagonist therapy for the prophylaxis of radiotherapy-induced nausea and vomiting: a systematic review of randomized and non-randomized studies. J Radiat Oncol 2(3):271–284.  https://doi.org/10.1007/s13566-012-0030-2 CrossRefGoogle Scholar
  30. 30.
    Brearley SG, Clements CV, Molassiotis A (2008) A review of patient self-report tools for chemotherapy-induced nausea and vomiting. Support Care Cancer 16(11):1213–1229.  https://doi.org/10.1007/s00520-008-0428-y CrossRefGoogle Scholar
  31. 31.
    Molassiotis A, Saunders MP, Valle J, Wilson G, Lorigan P, Wardley A, Levine E, Cowan R, Loncaster J, Rittenberg C (2008) A prospective observational study of chemotherapy-related nausea and vomiting in routine practice in a UK cancer centre. Support Care Cancer 16(2):201–208.  https://doi.org/10.1007/s00520-007-0343-7 CrossRefGoogle Scholar
  32. 32.
    Dranitsaris G, Leung P, Warr D (2001) Implementing evidence based antiemetic guidelines in the oncology setting: results of a 4-month prospective intervention study. Support Care Cancer 9:611–618.  https://doi.org/10.1007/s005200100273 CrossRefGoogle Scholar
  33. 33.
    Foubert J, Vaessen G (2005) Nausea: the neglected symptom? Eur J Oncol Nurs 9(1):21–32.  https://doi.org/10.1016/j.ejon.2004.03.006 CrossRefGoogle Scholar
  34. 34.
    Olver I, Molassiotis A, Aapro M, Herrstedt J, Grunberg S, Morrow G (2011) Antiemetic research: future directions. Support Care Cancer 19(1):49–55.  https://doi.org/10.1007/s00520-010-1036-1 CrossRefGoogle Scholar
  35. 35.
    Herrington JD, Jaskiewicz AD, Song J (2008) Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer 112(9):2080–2087.  https://doi.org/10.1002/cncr.23364 CrossRefGoogle Scholar
  36. 36.
    Grunberg SM, Deuson RR, Mavros P, Geling O, Hansen M, Cruciani G, Daniele B, de Pouvourville G, Rubenstein EB, Daugaard G (2004) Incidence of chemotherapy-induced nausea and emesis after modern antiemetics. Cancer 100(10):2261–2668.  https://doi.org/10.1002/cncr.20230 CrossRefGoogle Scholar
  37. 37.
    Stern A, Valaitis R, Weir R, Jadad AR (2012) Use of home telehealth in palliative cancer care: a case study. J Telemed Telecare 18(5):297–300.  https://doi.org/10.1258/jtt.2012.111201 CrossRefGoogle Scholar
  38. 38.
    Pirri C, Katris P, Trotter J, Bayliss E, Bennett R, Drummond P (2011) Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study. Support Care Cancer 19(10):1549–1563.  https://doi.org/10.1007/s00520-010-0982-y CrossRefGoogle Scholar
  39. 39.
    Tremblay P-B, Kaiser R, Sezer O, Rosler N, Schelenz C, Possinger K et al (2003) Variations in the 5-hydroxytryptamine type 3B receptor gene as predictors of the efficacy of antiemetic treatment in cancer patients. J Clin Oncol 21(11):2147–2155.  https://doi.org/10.1200/JCO.2003.05.164 CrossRefGoogle Scholar
  40. 40.
    Lee VHF, Ng SCY, Leung TW, Au GKH, Kwong DLW (2012) Dosimetric predictors of radiation-induced acute nausea and vomiting in IMRT for nasopharyngeal cancer. Int J Radiat Oncol Biol Phys 84(1):176–182.  https://doi.org/10.1016/j.ijrobp.2011.10.010 CrossRefGoogle Scholar
  41. 41.
    Saito M, Aogi K, Sekine I, Yoshizawa H, Yanagita Y, Sakai H, Inoue K, Kitagawa C, Ogura T, Mitsuhashi S (2009) Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial. Lancet Oncol 10(2):115–124.  https://doi.org/10.1016/S1470-2045(08)70313-9 CrossRefGoogle Scholar
  42. 42.
    Popovic M, Warr DG, DeAngelis C, Tsao M, Chan KKW, Poon M, Yip C, Pulenzas N, Lam H, Zhang L, Chow E (2014) Efficacy and safety of palonosetron for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV): a systematic review and meta-analysis of randomized controlled trials. Support Care Cancer 22(6):1685–1697.  https://doi.org/10.1007/s00520-014-2175-6 CrossRefGoogle Scholar
  43. 43.
    Dimitrijevic J, Snezana B, Medic-Milijic N (2009) Prevention of nausea and vomiting induced by chemotherapy followed by combined chemo/radiotherapy in head and neck cancer patients [abstract]. Support Care Cancer 17:02–009Google Scholar
  44. 44.
    Ganesh V, Drost L, DeAngelis C, Wan BA, Pasetka M, Chan S, Zhang L, Tsao M, Barnes E, Pulenzas N, Chung H, Zaki P, Yee C, Chow E (2018) A pilot study with palonosetron in the prophylaxis of radiation-induced nausea and vomiting. Ann Palliat Med 7(2):211–220CrossRefGoogle Scholar
  45. 45.
    Ganesh V, Chan S, Zhang L, Drost L, DeAngelis C, Wan BA et al (2018) Management of radiation-induced nausea and vomiting with palonosetron in patients with pre-existing emesis: a pilot study. Ann Palliat Med 7(4):385–392CrossRefGoogle Scholar
  46. 46.
    Navari RM, Nagy CK, Gray SE (2013) The use of olanzapine versus metoclopramide for the treatment of breakthrough chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy. Support Care Cancer 21(6):1655–1663.  https://doi.org/10.1007/s00520-012-1710-6.1655-1663,Jun.2013.
  47. 47.
    Jordan K, Schmoll HJ, Aapro MS (2007) Comparative activity of antiemetic drugs. Crit Rev Oncol Hematol 61(2):162–175.  https://doi.org/10.1016/J.CRITREVONC.2006.08.003 CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Erin McKenzie
    • 1
  • Pearl Zaki
    • 1
  • Srinivas Raman
    • 1
  • Robert Olson
    • 2
  • Thomas McFarlane
    • 1
  • Carlo DeAngelis
    • 1
  • Stephanie Chan
    • 1
  • William Pidduck
    • 1
  • Yasmeen Razvi
    • 1
  • Ahmad Bushehri
    • 1
  • Edward Chow
    • 1
    • 3
    Email author
  1. 1.Sunnybrook Odette Cancer CentreUniversity of TorontoTorontoCanada
  2. 2.Department of Radiation Oncology, BC Cancer Centre for the NorthUniversity of Northern British Columbia, University of British ColumbiaVancouverCanada
  3. 3.Department of Radiation Oncology, Odette Cancer CentreSunnybrook Health Sciences CentreTorontoCanada

Personalised recommendations